| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 代加工业务(元) | - | - | 3,982,300.89 | - | 2,400,442.48 |
| 技术服务(元) | 4,500,000.00 | - | 2,886,204.82 | - | 1,351,231.59 |
| 技术授权许可(元) | 41,596,708.41 | - | 28,945,403.24 | - | 42,071,399.05 |
| 药品销售(元) | 472,451,555.27 | - | 406,073,932.45 | - | 356,280,221.83 |
| 抗肿瘤药物(元) | - | 120,380,346.84 | - | 132,942,624.59 | - |
| 自身免疫药物(元) | - | 801,024,883.22 | - | 601,790,657.10 | - |
| 其他(元) | - | 13,811,881.65 | - | 8,432,778.40 | 183,426.91 |
| 营业成本(元) | |||||
| 代加工业务(元) | - | - | 1,562,018.14 | - | 883,629.03 |
| 技术服务(元) | - | - | 468,687.74 | - | - |
| 技术授权许可(元) | - | - | - | - | - |
| 药品销售(元) | 101,122,207.99 | - | 96,256,566.17 | - | 132,571,096.48 |
| 抗肿瘤药物(元) | - | 74,502,766.92 | - | 98,259,229.41 | - |
| 自身免疫药物(元) | - | 118,252,890.85 | - | 128,617,297.91 | - |
| 其他(元) | - | 4,464,209.75 | - | 2,665,368.75 | 54,594.34 |
| 毛利(元) | |||||
| 代加工业务(元) | - | - | 2,420,282.75 | - | 1,516,813.45 |
| 技术服务(元) | - | - | 2,417,517.08 | - | - |
| 技术授权许可(元) | - | - | 28,945,403.24 | - | - |
| 药品销售(元) | 371,329,347.28 | - | 309,817,366.28 | - | 223,709,125.35 |
| 抗肿瘤药物(元) | - | 45,877,579.92 | - | 34,683,395.18 | - |
| 自身免疫药物(元) | - | 682,771,992.37 | - | 473,173,359.19 | - |
| 其他(元) | - | 9,347,671.90 | - | 5,767,409.65 | 128,832.57 |
| 毛利率(%) | |||||
| 代加工业务(%) | - | - | 60.78 | - | 63.19 |
| 技术服务(%) | - | - | 83.76 | - | - |
| 技术授权许可(%) | - | - | - | - | - |
| 药品销售(%) | 78.60 | - | 76.30 | - | 62.79 |
| 抗肿瘤药物(%) | - | 38.11 | - | 26.09 | - |
| 自身免疫药物(%) | - | 85.24 | - | 78.63 | - |
| 其他(%) | - | 67.68 | - | 68.39 | 70.24 |
| 收入构成(%) | |||||
| 代加工业务(%) | - | - | 0.90 | - | 0.60 |
| 技术服务(%) | 0.87 | - | 0.65 | - | 0.34 |
| 技术授权许可(%) | 8.02 | - | 6.55 | - | 10.46 |
| 药品销售(%) | 91.11 | - | 91.90 | - | 88.56 |
| 抗肿瘤药物(%) | - | 12.87 | - | 17.89 | - |
| 自身免疫药物(%) | - | 85.65 | - | 80.98 | - |
| 其他(%) | - | 1.48 | - | 1.13 | 0.05 |
| 毛利构成(%) | |||||
| 代加工业务(%) | - | - | 0.70 | - | 0.67 |
| 技术服务(%) | 0.00 | - | 0.70 | - | 0.00 |
| 技术授权许可(%) | 0.00 | - | 8.42 | - | 0.00 |
| 药品销售(%) | 100.00 | - | 90.17 | - | 99.27 |
| 抗肿瘤药物(%) | - | 6.22 | - | 6.75 | - |
| 自身免疫药物(%) | - | 92.52 | - | 92.12 | - |
| 其他(%) | - | 1.27 | - | 1.12 | 0.06 |